Neuronetics (NASDAQ:STIM) EVP William Andrew Macan Sells 14,120 Shares of Stock

Neuronetics, Inc. (NASDAQ:STIM) EVP William Andrew Macan sold 14,120 shares of the company’s stock in a transaction that occurred on Thursday, February 12th. The stock was sold at an average price of $1.65, for a total value of $23,298.00. Following the transaction, the executive vice president directly owned 673,561 shares in the company, valued at $1,111,375.65. The trade was a 2.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

William Andrew Macan also recently made the following trade(s):

• On Tuesday, February 10th, William Andrew Macan sold 3,485 shares of Neuronetics stock. The stock was sold at an average price of $1.55, for a total transaction of $5,401.75.

Neuronetics Stock Performance

Shares of Neuronetics stock opened at $1.38 on Thursday. The company has a market cap of $94.52 million, a PE ratio of -1.68 and a beta of 0.79. The company has a quick ratio of 2.09, a current ratio of 2.24 and a debt-to-equity ratio of 2.09. Neuronetics, Inc. has a 52 week low of $1.25 and a 52 week high of $5.92. The business has a 50 day moving average price of $1.69 and a 200-day moving average price of $2.38.

Institutional Trading of Neuronetics

Several hedge funds and other institutional investors have recently bought and sold shares of STIM. AdvisorShares Investments LLC boosted its stake in shares of Neuronetics by 8.3% during the 2nd quarter. AdvisorShares Investments LLC now owns 130,534 shares of the company’s stock valued at $456,000 after purchasing an additional 10,000 shares in the last quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors grew its stake in Neuronetics by 436.2% in the second quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors now owns 86,919 shares of the company’s stock worth $303,000 after purchasing an additional 70,709 shares during the period. R Squared Ltd bought a new position in Neuronetics in the second quarter worth $52,000. Centiva Capital LP lifted its position in Neuronetics by 110.2% during the third quarter. Centiva Capital LP now owns 117,322 shares of the company’s stock valued at $320,000 after buying an additional 61,501 shares during the period. Finally, EHP Funds Inc. bought a new stake in shares of Neuronetics during the 3rd quarter valued at $572,000. Institutional investors own 53.59% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Wall Street Zen raised shares of Neuronetics from a “sell” rating to a “hold” rating in a report on Saturday, December 6th. Weiss Ratings restated a “sell (e+)” rating on shares of Neuronetics in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $7.00.

About Neuronetics

Neuronetics, Inc is a commercial‐stage medical technology company that develops and markets non-invasive neuromodulation therapies for psychiatric and neurological disorders. The company’s flagship product, the NeuroStar Advanced Therapy System, uses repetitive transcranial magnetic stimulation (rTMS) to deliver targeted magnetic pulses to areas of the brain implicated in major depressive disorder (MDD). NeuroStar Advanced Therapy has received U.S. Food and Drug Administration clearance for the treatment of adults with treatment-resistant depression and is supported by a growing body of clinical evidence demonstrating its safety and efficacy.

Founded in 2003 and headquartered in Malvern, Pennsylvania, Neuronetics focuses on advancing clinical care through innovation in neurostimulation.